A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO'CONTROLLED ASCENDING DOSE STUDY to EVALUATE the SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) and PHARMACODYNAMIC (PD) EFFECTS of POSIPHEN® in SUBJECTS with MILD ALZHEIMER'S DISEASE/ MCI

Authors
Category Primary study
ConferenceJournal of Prevention of Alzheimer's Disease
Year 2022
This article has no abstract
Epistemonikos ID: 7a8e52837d3aae945fc31bc0184736c4531e718d
First added on: Apr 30, 2026